XML 44 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Description of Business and Basis of Presentation - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2016
USD ($)
shares
Sep. 30, 2016
USD ($)
Payment
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 23, 2014
USD ($)
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Accumulated deficit   $ (2,791,540,000) $ (2,791,540,000)   $ (2,863,229,000)    
Number of shares sold in a registered public offering | shares 48,543,692            
Proceeds from offering of common stocks and warrants, net $ 47,400,000   772,000 $ 13,524,000      
Cash and cash equivalents   35,530,000 35,530,000 $ 32,928,000 59,074,000 $ 120,841,000  
Amount available for future borrowings   30,100,000 30,100,000        
Net revenue from collaboration   161,781,000 161,781,000        
Net revenue - commercial product sales   573,000 573,000        
Deferred revenue   $ 2,014,000 $ 2,014,000        
Cash discount as incentive for prompt payment   2.00% 2.00%        
Third party logistics              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Deferred revenue   $ 1,600,000 $ 1,600,000        
Third Party              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Deferred revenue   400,000 $ 400,000        
License and Collaboration Agreement with Sanofi              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Profits and losses sharing percentage     35.00%        
Maximum secured loan facility             $ 175,000,000
Net revenue from collaboration   161,800,000 $ 161,800,000        
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Profits and losses sharing percentage     65.00%        
Maximum secured loan facility   175,000,000 $ 175,000,000        
Deferred sales from collaboration product shipments   150,000,000 150,000,000        
Milestone receivable   25,000,000 25,000,000        
Deferred cost         13,500,000    
Net revenue from collaboration   17,400,000          
Up-front fee   $ 150,000,000          
Number of milestone payment | Payment   2          
Milestone payments earned   $ 25,000,000 $ 25,000,000        
Net loss share payments   (64,800,000)          
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | Insulin Put              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Net revenue from collaboration   9,200,000          
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH | AFREZZA product sales              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Deferred sales from collaboration product shipments         $ 17,500,000    
Maximum              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Number of warrants available for purchase common shares | shares 48,543,692            
Maximum | AFREZZA product sales              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Sales return right following product expiration in months     12 months        
Minimum | AFREZZA product sales              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Sales return right following product expiration in months     6 months        
Senior convertible notes due December 31, 2019 | Deerfield | Minimum | Less portion of commitment asset              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Available amount of credit facility under covenant restrictions   $ 25,000,000 $ 25,000,000